Health · 1 sources covering this

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/64c64ad1149184ff47944d9fc0b9ccf9caaf975d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug"></iframe>

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

How 1 sources are covering this

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

More from Health

Did Russia play by the rules in reporting lab worker's death?

STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds

STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertainty

STAT+: Up and down the ladder: The latest comings and goings

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

More from Health

Did Russia play by the rules in reporting lab worker's death?

STAT+: Pharma&#8217;s free lunches for doctors boost inappropriate prescribing, analysis finds

STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertainty

STAT+: Up and down the ladder: The latest comings and goings

Reader

Trust & legal

Across the network

STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds